SANJAY DESHPANDE to Adult
This is a "connection" page, showing publications SANJAY DESHPANDE has written about Adult.
Connection Strength
0.033
-
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial. Leukemia. 2022 10; 36(10):2479-2487.
Score: 0.012
-
Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Lymphoma. 2022 07; 63(7):1580-1588.
Score: 0.012
-
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. J Clin Oncol. 2018 08 10; 36(23):2405-2412.
Score: 0.009